Inozyme Pharma, Inc.

Equities

INZY

US45790W1080

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
7.66 USD +3.65% Intraday chart for Inozyme Pharma, Inc. +30.49% +79.81%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Inozyme Pharma, Inc. to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency CI
Inozyme Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy in Genomics England's Generation Study of Rare Conditions CI
Inozyme Pharma, Inc. Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency CI
Inozyme Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Insider Buy: Inozyme Pharma MT
Sector Update: Health Care Stocks Rising Late Friday MT
Sector Update: Health Care MT
Inozyme Pharma Prices $60 Million Share Offering MT
Sector Update: Health Care Stocks Declining Late Wednesday MT
Sector Update: Health Care Stocks Falling Wednesday Afternoon MT
Sector Update: Health Care MT
Inozyme Pharma Updates INZ-701 Development Plan After Meetings With US, EU Regulators; Shares Drop MT
Transcript : Inozyme Pharma, Inc. - Special Call
Inozyme Pharma, Inc. Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency CI
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in Phase 1b Trial of INZ-701 CI
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell Small Cap Comp Value Index CI
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell 3000 Index CI
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell 3000E Index CI
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell Small Cap Completeness Index CI
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell 2500 Index CI
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell 2000 Index CI
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell 3000E Value Index CI
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell 3000 Value Index CI
Chart Inozyme Pharma, Inc.
More charts
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Company’s lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to cleave extracellular adenosine triphosphate (ATP) to generate plasma pyrophosphate (PPi) and adenosine monophosphate (AMP), which can be processed to phosphate and adenosine. Its INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
7.66 USD
Average target price
21 USD
Spread / Average Target
+174.15%
Consensus
  1. Stock
  2. Equities
  3. Stock Inozyme Pharma, Inc. - Nasdaq
  4. News Inozyme Pharma, Inc.
  5. Inozyme Pharma : Q2 Loss Narrows, Operating Expenses Rise